Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP

The study was conducted from October 2020 to March 2022 in a province in southern Thailand. The inpatients with community-acquired pneumonia (CAP) and more than 18 years old were enrolled. Of the 1511 inpatients with CAP, COVID-19 was the leading cause, accounting for 27%. Among the patients with COVID-19 CAP, mortalities, mechanical ventilators, ICU admissions, ICU stay, and hospital costs were significantly higher than of those with non-COVID-19 CAP. Household and workplace contact with COVID-19, co-morbidities, lymphocytopenia and peripheral infiltration in chest imaging were associated with CAP due to COVID-19. The delta variant yielded the most unfavorable clinical and non-clinical outcomes. While COVID-19 CAP due to B.1.113, Alpha and Omicron variants had relatively similar outcomes. Among those with CAP, COVID-19 infection as well as obesity, a higher Charlson comorbidity index (CCI) and APACHE II score were associated with in-hospital mortality. Among those with COVID-19 CAP, obesity, infection due to the Delta variant, a higher CCI and higher APACHE II score were associated with in-hospital mortality. COVID-19 had a great impact on the epidemiology and outcomes of CAP.

[1]  Ploy N. Pratanwanich,et al.  Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study , 2022, The Lancet Regional Health - Southeast Asia.

[2]  D. H. Farkas,et al.  Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants , 2022, The Journal of infectious diseases.

[3]  M. Stepanova,et al.  The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19 , 2022, BMC Infectious Diseases.

[4]  M. Bhattacharya,et al.  Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape , 2022, Folia Microbiologica.

[5]  K. Khunti,et al.  Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study , 2022, BMJ.

[6]  Yoshihiro Kitahara,et al.  Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility , 2022, Respiratory Investigation.

[7]  A. Vyse,et al.  Hospitalization costs of adult community-acquired pneumonia in England , 2022, Journal of medical economics.

[8]  C. Stephani,et al.  Janus kinase inhibitors for the treatment of COVID-19. , 2022, The Cochrane database of systematic reviews.

[9]  J. Skarbinski,et al.  Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.

[10]  Boonsub Sakboonyarat,et al.  Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital , 2022, Scientific Reports.

[11]  P. Chaturvedi,et al.  Outcomes of COVID-19 and risk factors in patients with cancer , 2022, Nature Cancer.

[12]  J. Knight,et al.  SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.

[13]  Michael C. McGee,et al.  Mutations and Evolution of the SARS-CoV-2 Spike Protein , 2022, Viruses.

[14]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[15]  A. Apisarnthanarak,et al.  Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study , 2022, Emerging microbes & infections.

[16]  K. Kahnert,et al.  Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire , 2022, Respiratory Research.

[17]  S. Murthy,et al.  Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial , 2022, Canadian Medical Association Journal.

[18]  Yuemei Li,et al.  The Impact of COVID-19 on Cancer , 2021, Infection and drug resistance.

[19]  Janet S. Lee,et al.  Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease , 2021, PLoS pathogens.

[20]  C. Chakraborty,et al.  D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin? , 2021, Molecular Therapy - Nucleic Acids.

[21]  Peng Zheng,et al.  N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2 , 2021, eLife.

[22]  N. Skoetz,et al.  Systemic corticosteroids for the treatment of COVID-19. , 2021, The Cochrane database of systematic reviews.

[23]  Vineet D. Menachery,et al.  Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant , 2021, bioRxiv.

[24]  Joshua B. Singer,et al.  Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.

[25]  J. Rello,et al.  COVID-19-Associated Pulmonary Aspergillosis (CAPA) , 2021, Journal of Intensive Medicine.

[26]  E. Undurraga,et al.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.

[27]  M. Khan,et al.  Causes of hospitalization in the USA between 2005 and 2018 , 2021, European heart journal open.

[28]  S. Maurer-Stroh,et al.  Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Navkiran K. Shokar,et al.  A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19 , 2021, Scientific Reports.

[30]  I. Boutron,et al.  Interleukin-6 blocking agents for treating COVID-19: a living systematic review. , 2021, The Cochrane database of systematic reviews.

[31]  K. Knox,et al.  ACE2: At the crossroad of COVID-19 and lung cancer , 2021, Gene Reports.

[32]  K. Badani,et al.  Association between chronic kidney disease and COVID-19-related mortality in New York , 2021, World Journal of Urology.

[33]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[34]  K. Rand,et al.  Performance of a Semiquantitative Multiplex Bacterial and Viral PCR Panel Compared With Standard Microbiological Laboratory Results: 396 Patients Studied With the BioFire Pneumonia Panel , 2020, Open forum infectious diseases.

[35]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[36]  O. Slabý,et al.  Is the “Common Cold” Our Greatest Ally in the Battle Against SARS-CoV-2? , 2020, Frontiers in Cellular and Infection Microbiology.

[37]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[38]  Christopher A. Lazarski,et al.  SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein , 2020, Blood.

[39]  Sheng Lin,et al.  The chest CT features of coronavirus disease 2019 (COVID-19) in China: a meta-analysis of 19 retrospective studies , 2020, Virology journal.

[40]  M. Lipsitch,et al.  Cross-reactive memory T cells and herd immunity to SARS-CoV-2 , 2020, Nature Reviews Immunology.

[41]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[42]  D. Kerr,et al.  COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.

[43]  Lee-Jen Wei,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[44]  G. Cohen Immune Dysfunction in Uremia 2020 , 2020, Toxins.

[45]  Suqin Ben,et al.  Meta‐analysis of chest CT features of patients with COVID‐19 pneumonia , 2020, Journal of medical virology.

[46]  M. Djalali,et al.  Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

[47]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[48]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[49]  A. Allard,et al.  Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections , 2020, Infectious diseases.

[50]  J. Rello,et al.  Community-acquired bacterial pneumonia in adults: An update , 2020, The Indian journal of medical research.

[51]  Robert J. Mason,et al.  Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.

[52]  G. Lippi,et al.  Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection , 2020, International Urology and Nephrology.

[53]  Han Zhang,et al.  Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis , 2020, Journal of the American College of Radiology.

[54]  Tian Huang,et al.  COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.

[55]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[56]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[57]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[58]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[59]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[60]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[61]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[62]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[63]  M. Fine,et al.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.

[64]  A. Pfeiffer,et al.  Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation , 2019, Immunity & Ageing.

[65]  William A. Mattingly,et al.  Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  K. Huh,et al.  Community-Acquired Pneumonia in the Asia-Pacific Region , 2016, Seminars in Respiratory and Critical Care Medicine.

[67]  M. Ebell,et al.  Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis , 2016, The Annals of Family Medicine.

[68]  D. Chung,et al.  Community-acquired pneumonia requiring hospitalization among U . S . adults , 2016 .

[69]  Á. Gentile [U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination]. , 2014, Archivos argentinos de pediatria.

[70]  Y. Thavornpitak,et al.  Burden of adult pneumonia in Thailand: a nationwide hospital admission data 2010. , 2014, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[71]  Lauren M Wier,et al.  Costs for Hospital Stays in the United States, 2010 , 2013 .

[72]  T. Schaberg,et al.  Guidelines for the management of adult lower respiratory tract infections ‐ Full version , 2011, Clinical Microbiology and Infection.

[73]  C. Esquinas,et al.  Microbial aetiology of community-acquired pneumonia and its relation to severity , 2011, Thorax.

[74]  Margaret A Dudeck,et al.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.

[75]  A. Anzueto,et al.  A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.

[76]  M. Afzal Health research in the World Health Organization Regional Office for the Eastern Mediterranean. , 2008, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[77]  S. Lochindarat,et al.  Prevalence and clinical presentations of atypical pathogens infection in community acquired pneumonia in Thailand. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[78]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[79]  J. M. Martínez Vázquez,et al.  Etiology of community-acquired pneumonia , 2005, European Journal of Clinical Microbiology.

[80]  Gilles Clermont,et al.  Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. , 2002, American journal of respiratory and critical care medicine.

[81]  P. Brown,et al.  Community-acquired pneumonia: An overview , 1999, Current infectious disease reports.

[82]  C. Ellenbogen The common cold. , 1981, American family physician.